Rational Design of Proteomimetics to Disrupt SARS-CoV-2 S-RBD/hACE2 Interaction

Study Background and Research Question

Protein–protein interactions (PPIs) underpin a wide spectrum of biological processes, including cellular communication, signaling regulation, and structural organization. In the context of viral infection, PPIs between pathogen and host elements are critical determinants of infectivity and immune response. The COVID-19 pandemic, driven by the interaction between the SARS-CoV-2 Spike receptor-binding domain (S-RBD) and the human angiotensin-converting enzyme 2 (hACE2), highlighted the urgent need for effective inhibitors targeting this large and shallow PPI interface. Traditional small-molecule inhibitors have proven largely ineffective against such interfaces due to their size and lack of well-defined pockets, prompting research into alternative modalities for disrupting the S-RBD/hACE2 interaction (Ferková et al., J. Med. Chem.).

Key Innovation from the Reference Study

The study by Ferková and colleagues advances the field by introducing a structure-guided strategy to design proteomimetics—engineered peptide-based molecules—capable of mimicking critical recognition elements of hACE2. Specifically, the team focused on two secondary structural motifs: the α1 helix (residues Glu23-Ser44) and an antiparallel β-sheet segment (Thr347-Leu359) from hACE2, both of which are essential for binding the SARS-CoV-2 S-RBD. To stabilize these motifs, the researchers employed peptide stapling and head-to-tail macrocyclization, respectively. The subsequent covalent linkage of both elements yielded a composite proteomimetic (compound 28) that preserves the spatial arrangement needed for selective S-RBD engagement. This approach exemplifies a rational, modular design for targeting otherwise undruggable PPIs (reference study).

Methods and Experimental Design Insights

The research leveraged in silico alanine scanning mutagenesis to identify key hACE2 residues at the S-RBD interface, guiding the selection of structural segments for mimicry. The α1-helix mimetics were stabilized using hydrocarbon peptide stapling, a strategy known to enhance helicity and proteolytic resistance. For the β-sheet region, the team used head-to-tail macrocyclization incorporating a D-Pro/L-Pro motif, which enforces the antiparallel β-sheet conformation. The two constrained mimetics were then covalently fused to form compound 28.

Biophysical assays, including surface plasmon resonance and cellular pseudovirus entry experiments, were performed to characterize binding affinity, specificity, and antiviral efficacy. Compound 28's stability and permeability were evaluated using lung epithelial cell models, relevant to the route of SARS-CoV-2 infection.

Core Findings and Why They Matter

Compound 28 demonstrated selective binding to the SARS-CoV-2 S-RBD and effectively disrupted the S-RBD/hACE2 interaction in both biophysical and cell-based assays. Functional pseudovirus entry inhibition was achieved with an IC₅₀ of 6.6 μM. Notably, the proteomimetic displayed high stability (t_1/2 > 24 h) in lung epithelial models and exhibited low epithelial permeability (Papp = 2.03 × 10⁻⁸ cm·s⁻¹), suggesting its suitability for intranasal administration. These properties address two major challenges for peptide-based antivirals: proteolytic degradation and non-specific tissue distribution (reference study).

Importantly, this study provides a proof-of-concept for the broader applicability of structure-guided, modular peptide design in targeting challenging viral-host PPIs. The demonstrated stability and activity in physiologically relevant cell models represent meaningful advances over previous approaches relying on small-molecule or antibody-based inhibitors, which often lack specificity or present manufacturability barriers.

Comparison with Existing Internal Articles

Recent internal articles, such as "Structure-Guided Proteomimetics Disrupt SARS-CoV-2 S-RBD/hACE2 PPI", independently underscore the therapeutic promise of engineered proteomimetics for antiviral intervention. These resources emphasize that rational design—guided by high-resolution structural and computational analyses—enables targeting PPIs previously considered undruggable. In parallel, internal research on Camostat Mesilate in Translational Protease Inhibition Strategies explores complementary approaches for modulating protease activity, a mechanistic axis indirectly relevant to viral entry and tissue remodeling.

While Camostat Mesilate is primarily a trypsin-like protease inhibitor used to study inhibition of airway epithelial sodium channel function and suppression of TGF-β generation, the structure-guided proteomimetic approach targets PPIs directly at the viral-host interface. The juxtaposition of these strategies highlights the diversity of molecular toolkits available to dissect and disrupt pathogenic processes in respiratory disease and fibrosis research.

Limitations and Transferability

Despite its promising findings, the study’s peptide-based proteomimetic approach faces several limitations. First, while compound 28 exhibits favorable stability and selective antiviral activity in vitro and in cellular models, its in vivo pharmacokinetics, toxicity, and immunogenicity remain uncharacterized. The low permeability observed in lung epithelial models may be advantageous for local delivery but could limit systemic efficacy if broader distribution is required.

Transferability to other class III PPIs will depend on the availability of high-resolution structural data and the feasibility of designing stable, conformationally constrained mimetics for each target. Furthermore, large-scale manufacturing and delivery of stapled peptides or macrocyclic constructs may present translational challenges compared to small molecules or biologics.

Why this cross-domain matters, maturity, and limitations

The bridge between direct viral PPI disruption and host protease inhibition strategies is of particular interest in respiratory research. While the reference study targets the viral-host interface, complementary approaches such as inhibition of plasmin activity or blockade of hepatic stellate cell activation—exemplified by Camostat Mesilate use—address downstream inflammatory and fibrotic sequelae. However, the cross-domain translation of structure-guided proteomimetics to other protease-mediated pathologies is not directly established by this reference and requires further empirical validation.

Protocol Parameters

• Peptidomimetic design: Select hACE2 interface segments based on computational alanine scanning; stabilize α-helix with peptide stapling (e.g., Glu23-Ser44), and β-sheet with macrocyclization (e.g., Thr347-Leu359).
• Compound synthesis: Employ hydrocarbon stapling and D-Pro/L-Pro macrocyclization; covalently link stabilized segments.
• In vitro binding assays: Use surface plasmon resonance or equivalent biophysical techniques to confirm S-RBD binding specificity and affinity.
• Pseudovirus entry assays: Assess inhibition of SARS-CoV-2 pseudovirus entry into hACE2-expressing cells; report IC₅₀ values for direct comparison.
• Stability and permeability: Evaluate half-life (>24 h) and epithelial permeability (Papp) in lung cell models.
• Workflow suggestion: For translational research in airway or fibrosis models, pair direct PPI inhibition studies with established protease inhibition protocols as appropriate.

Research Support Resources

For researchers investigating protease-mediated mechanisms in airway and fibrosis models, Camostat Mesilate (SKU B2082) from APExBIO is a potent trypsin-like protease inhibitor that enables precise modulation of ENaC function and TGF-β signaling. Its high solubility in DMSO and water, as described in the product information, facilitates workflow integration for studies requiring inhibition of plasmin activity or blockade of hepatic stellate cell activation. While the current reference focuses on structure-guided disruption of viral-host PPIs, Camostat Mesilate remains a well-characterized tool for complementary research in protease biology and fibrosis.